Brought to you by 
Eyevance acquires US rights to Novartis' topical ophthalmic corticosteroid Flarex
22 Apr 2021
Executive Summary
Eyevance Pharmaceuticals LLC acquired exclusive US rights to Novartis AG's Flarex (fluorometholone acetate) ophthalmic suspension 0.1% for multiple ocular inflammation and pain indications.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Eyevance acquires US rights to Novartis' topical ophthalmic corticosteroid Flarex
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice